Zealand Pharma A/S is a biotechnology company that designs and develops peptide therapeutics to treat metabolic and gastrointestinal diseases. Founded in 1998 and headquartered in Copenhagen, the company leverages its proprietary technology platform to create medicines that mimic or replace natural peptide hormones in the human body. Its research and development pipeline is heavily focused on next-generation treatments for obesity, type 2 diabetes, and rare diseases. Rather than commercializing products independently, Zealand Pharma typically partners with large pharmaceutical firms—such as Roche, Boehringer Ingelheim, and Novo Nordisk—to fund late-stage clinical trials, manufacturing, and global distribution. The company generates revenue primarily through upfront payments, development milestones, and royalties tied to these collaborative agreements. In addition to its Danish headquarters, the company maintains a corporate presence in the United States.
